GLP-1-based therapyglucagon-like peptide-1 (GLP-1) based therapydiabetes mellitusGLP-1 receptor agonist
…py (adjusted β+83 min, 95% CI 3.1 to 162.8; p=0.042).Conclusion GLP-1-based therapy was associated with longer small-bowel transit time during caps…